Mucositis News and Research

RSS

Tetracaine mouthwash helps with pain linked to head and neck cancer

Doctors in Italy are studying whether a new type of mouthwash will help alleviate pain for patients suffering from head and neck cancer who were treated with radiation therapy, according to a study published in the International Journal of Radiation Oncology-Biology-Physics

13 Feb 2006

Intensity modulated radiation therapy (IMRT) for head and neck cancer

Results from a University of Pittsburgh study evaluating intensity modulated radiation therapy (IMRT) for head and neck cancer determined the ideal doses for lessening treatment side effects. The findings were presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.

18 Oct 2005

Preclinical data suggest CuraGen's Velafermin may protect the gastrointestinal tract and decrease associated toxicity following exposure to radiation

New preclinical data on velafermin (CG53135), CuraGen's Phase II clinical product being developed for the prevention of oral mucositis (OM), suggesting that velafermin may protect the gastrointestinal tract and decrease associated toxicity, including enteritis and diarrhea, following exposure to radiation.

1 Jul 2005

Simple analysis of a bone marrow transplant patient's oral rinse indicates whether infection will develop

Simple analysis of a bone marrow transplant patient's oral rinse can give medical personnel a quick indication of the transplant's effectiveness and predict whether an infection will develop, says a University of Toronto researcher.

27 Jun 2005

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.

26 Oct 2004

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire all outstanding equity of Aesgen for $32 million in cash.

1 Sep 2004